



To: Washington University IRB

From: Zachary Prensky, CEO - LB Pharmaceuticals

Date: June 27, 2021

RE: Clarification Memo #8

An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects

---

The intent of this memo is to justify an increase in compensation (\$375) for Subject 01S0017. This Subject's Pre-Dose Scan Visit was originally scheduled for 24 Jun 2021, starting at 9:00 AM CST. The Subject's Pre-Dose Scan Visit had to be rescheduled to 25 Jun 2021, but the Subject was provided notice less than 12 hours prior to their Visit. This prompt rescheduling led to a loss of income for Subject 01S0017.

In response, the Sponsor has agreed to provide additional compensation to Subject 01S0017.

ZACHARY PRENSKY

Zachary Prensky, CEO

Signature

Date